I nfluenza A viruses cause annual epidemics among humans, necessitating frequent updates of seasonal influenza vaccines. Despite tremendous efforts to match the haemagglutinin (HA) antigenicity of vaccine strains to that of the circulating influenza viruses, vaccine effectiveness for one or more of the vaccine components can still be low. A(H3N2) virus predominated during recent influenza seasons, causing a significant number of hospitalizations in many countries, with excess mortality in elderly people [1] [2] [3] [4] . In the 2017 Southern Hemisphere influenza season, the number of A(H3N2) influenza notifications in Australia far exceeded the cases reported during the 2009 A(H1N1) influenza pandemic 3 . Vaccine effectiveness estimates for A(H3N2) virus in the United States during the 2014-15, 2016-17 and 2017-18 seasons were approximately 6%, 32% and 25%, respectively 5, 6 . The estimates were even lower in other areas of the world: 17% during the 2017-18 season in Canada and 10% during the 2017 season in Australia 2,3,7 .
The poor vaccine performance against A(H3N2) virus has mostly been attributed to a mismatch between the HA genetic clades of vaccine strains and the circulating A(H3N2) viruses 8, 9 , and amino acid mutations in HA-for example, L194P and T160K-that occurred during the egg-based virus isolation and vaccine-manufacturing process 10, 11 . However, solid data for the superiority of vaccines with-out these mutations (for example, cell-based inactivated vaccines and recombinant HA-based vaccines) are lacking. Neuraminidase (NA)-specific immunity also provides protection against influenza, and antibodies against HA and NA contribute independently to the protection [12] [13] [14] ; however, the importance of NA-specific immunity has long been neglected. Like HA, NA acquires point mutations during the circulation of influenza viruses, which results in a change in antigenicity-the so-called antigenic drift 15, 16 . In this study, we have identified an N-linked glycosylation site at NA residue 245 (NA245) of circulating A(H3N2) viruses, which significantly reduces the binding of NA by antibodies, including broadly-reactive human monoclonal antibodies, to a previously conserved NA epitope; we demonstrate that the glycosylation at NA245 and a P468H mutation have become fixed in the A(H3N2) viruses circulating since 2016 and contributed to the NA antigenic drift of these viruses, which is consistent with reduced protection against virus challenge in the mouse model. viruses available in public databases ( Fig. 1a ), we found that amino acid mutations at residues 245 and 247 are of special interest. Following the outbreak of pandemic A(H3N2) virus in 1968, the S245N mutation was present in the NA of some A(H3N2) isolates in 1969, 1974 and 1977 (Fig. 1b ), but it was not detected again until more than 20 years later. Then, in 2014, this mutation was present in more A(H3N2) viruses and the double mutation S245N/S247T also emerged. This double mutation rapidly surged to be in approximately 50% of A(H3N2) isolates in 2015 and it was present in nearly all A(H3N2) viruses circulating in humans by 2016 and 2017 ( Fig.  1b) . Interestingly, this double mutation occurred in the NA of A(H3N2) strains of the 3C.2a HA clade and various subclades but not in the 3C.3a and 3C.3b clades ( Supplementary Table 1 ). Both S245N and S245N/S247T mutations are predicted to introduce an N-linked glycosylation site at NA245, which prompted us to investigate the effect of these mutations on NA antigenicity and the in vivo protection against virus infection.
We performed western blot analysis with the wild-type (WT) NAs of A/Hong Kong/4801/2014 (HK/14) and A/Singapore/ INFIMH-16-0019/2016 (SGP/16), as well as mutant HK/14 and SGP/16 NAs that bear mutations that introduce or remove the NA245 glycosylation site (Fig. 1c ). HK/14 is representative of earlier A(H3N2) viruses that lacked the NA245 glycosylation site (encoded S245/A246/S247; Supplementary Fig. 1 ), whereas SGP/16 is typical of A(H3N2) viruses circulating at present that possess the potential NA245 glycosylation site motif N245/A246/T247. HK-245N and HK-245N/247T-that is, HK/14 NAs with the S245N and S245N/ S247T mutations, respectively-migrated at a higher molecular weight than WT HK/14 NA, whereas mutant SGP/16 NA with the N245S mutation (SGP-245S) migrated at a lower molecular weight than WT SGP/16 NA ( Fig. 1c) , indicating that the S245N and S245N/S247T mutations indeed result in glycosylation at NA245.
The glycosylation at NA245 was also verified by glycoproteomics-mass spectrometry, which showed that glycans are present at residue 245 in the NA of WT SGP/16 but not of mutant SGP-245S ( Supplementary Fig. 2 ). Glycans added to residue 245 are mainly complex N-linked glycans ( Fig. 1d ), which can be expected to provide a large hydrodynamic radius covering the protein backbone near it.
Glycosylation at NA245 and a mutation at residue 468 result in significant NA antigenic drift. The glycosylation at NA245 decreases NA activity, as indicated by enzyme-linked lectin assay (ELLA) 17 as well as MU-NANA (a fluorescence assay using 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MU-NANA) sodium salt as substrate) 18, 19 and plaque assays ( Supplementary Fig. 3 ). The 250-loop is an important antigenic domain on NA 18, 20, 21 ; we therefore proceeded to investigate whether the glycosylation at NA245 also affects NA antigenicity. Ferret antisera raised against A(H3N2) vaccine viruses that lacked the NA245 glycosylation site-for example, A/Victoria/361/2011 H3N2  H3N3  H3N4  H3N5  H3N7  H3N9  H4N2  H4N3  H4N5  H4N6  H4N9  H5N6  H5N8F1  H6N5  H6N9  H7N2  H7N7F1  H8N8F1  H4N3F1  H4N4F1  H4N7F1  H3N5F1 H3N8F1 H3N2F1 H3N3F1 The image is representative of two technically independent experiments that yielded similar results (the image generated with data from the other experiment is shown in Supplementary Fig. 8 ). d, Profile of N-linked glycosylation on the NA of WT SGP/16. Analysis was performed by mass spectrometry with A(H6N2) virus containing the NA from WT SGP/16 (H6N2 SGP/16 ). Three technically independent experiments were performed and yielded similar results; the data from one of the experiments are shown (data from the other two experiments are shown in Supplementary Fig. 8 ).
(VIC/11), A/Texas/50/2012 (TX/12), A/Switzerland/9715293/2013 (SWZ/13) and HK/14-were tested for inhibition of SGP/16 NA ( Supplementary Fig. 1 ). These antisera exhibited significantly reduced (between 16-and 32-fold) inhibition of SGP/16 NA, whereas ferret antisera against SGP/16 had NA inhibition (NI) titres that were ≥4-fold lower than the homologous titres to these vaccinevirus NAs (except VIC/11 NA; Fig. 2a and Supplementary Table 2 ). These results suggest significant NA antigenic drift between the circulating A(H3N2) viruses and vaccine strains. Inhibition by ferret antisera against VIC/11 and HK/14 recovered when a N245S mutation was introduced in the SGP/16 NA to remove the glycosylation site (Supplementary Table 2 ), highlighting the critical role of the NA245 glycosylation site in the observed NA antigenic drift. The inhibition of HK/14 NA by ferret antisera against HK/14 was not significantly affected by the introduction of the NA245 glycosylation site alone (S245N or S245N/S247T; Fig. 2a and Supplementary Table 2 ), which implies that other amino acid substitutions also contributed to the NA antigenic change. In addition to the amino acid differences at residues 245 and 247, there are variations between the HK/14 and SGP/16 NAs at residues 212, 231, 267, 339, 380, 392 and 468 ( Supplementary Fig. 1 ). Of these, residue 212 is on the bottom surface of the NA head and residue 231 is not on the NA surface, such that neither is likely to affect NA antigenicity; furthermore, the individual introduction of the residues found in SGP/16 NA into the HK/14 NA at positions 247, 267, 339, 380, 392 or 468 resulted in a minimal loss of NI titres of HK/14 ferret antisera (≤2-fold; Supplementary Table 2 ).
We then introduced each of the residues of the SGP/16 NA at positions 267, 339, 380, 392 and 468 into the HK-245N/247T NA. Only the mutation at position 468 (that is, from a P in HK-245N/247T Table 3 ). WT HK/14 (blue); WT MIE/16, SGP/16 and LA/17 (red); and SGP-245S (green) NAs are shown. d, Eleven of the 22 human serum samples described in c had NI titres that were ≥4-fold lower against the NA of at least one of the recent viruses (MIE/16, SGP/16 or LA/17) than against HK/14 NA; the titres against HK-245N/247T, HK-245N/247T/468H and SGP-245S NAs were also included for comparison. The data from one of two technically independent experiments that were run in duplicate and yielded similar results are shown (data from the other experiment are shown in Supplementary Fig. 8 ). The horizontal bars represent the mean titres (n = 11); the P values were calculated with one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison.
NA to an H in SGP/16 NA) resulted in significantly (8-fold) lower NI titres of HK/14 ferret antisera (Supplementary Table 2 ). The P468H mutation surged in 2015 and by 2016 the majority of circulating A(H3N2) viruses possessed the H468 in NA, with a small proportion of viruses bearing L468 ( Supplementary Fig. 4 ). Alone, this mutation had little effect on the inhibition of HK/14 NA by the homologous ferret antisera against HK/14 but enhanced (6-fold) the inhibition by SGP/16 ferret antisera. Similarly, the H468P substitution in SGP/16 NA resulted in efficient inhibition by HK/14 ferret antisera without a significant loss of inhibition by SGP/16 ferret antisera. A test with cell-grown viruses bearing the HK-245N/247T or HK-245N/247T/468H NAs revealed similar inhibition (Supplementary Table 2 ). These analyses suggest that the glycosylation at NA245 (due to the S245N/S247T substitutions) and a P468H mutation, which had been dominant in the circulating A(H3N2) viruses since 2016 ( Fig. 1b and Supplementary  Fig. 4 ), contributed to NA antigenic drift in relation to the vaccine strain HK/14.
NA antigenic drift of circulating A(H3N2) viruses demonstrated by human sera.
The NA antigenic drift was also analysed with a panel of 36 human serum samples, all except one of which had detectable NI antibody titres (that is, ≥20, the starting dilution of serum samples in our assays) against the HK/14 NA ( Fig. 2b) . Because a fold change ≥4 in antibody titre is generally thought to be antigenically significant, only 22 samples exhibiting NI titres ≥80 against HK/14 NA ( Supplementary Table 3 Table 3 ), thus reflecting the NA antigenic difference between the circulating A(H3N2) viruses and the HK/14 vaccine strain ( Fig. 2c ). Furthermore, 11 of the 22 samples had a ≥4-fold reduction in NI titres against at least one of these recent virus NAs (MIE/16, SGP/16 and LA/17; Fig. 2d and Supplementary Table 3 ). Combined, the S245N/S247T (introducing the NA245 glycosylation site) and P468H mutations resulted in substantially reduced inhibition of NA, with 8 of 11 samples exhibiting ≥4-fold lower NI titres compared with the WT HK/14 NA, whereas the S245N/S247T double mutation alone has less impact. Interestingly, removal of the NA245 glycosylation site from the SGP/16 NA (by N245S mutation) restored the inhibition by human sera ( Fig. 2d and Supplementary  Table 3 ). Together, we confirmed the NA antigenic drift of circulating A(H3N2) viruses and the critical role of the NA245 glycosylation site and amino acid mutation at residue 468 with human serum samples.
NA antigenic drift is consistent with reduced binding by monoclonal antibodies. The NA antigenic drift was further investigated by testing the reactivity of human monoclonal antibodies 22 and the mouse monoclonal antibody B10 ( Fig. 3 ). Antibody B10 was raised against the NA of an A(H3N2)v swine-origin variant virus, A/Minnesota/11/2010 (MN/10; Supplementary Fig. 5 and Supplementary Tables 4,5 ). These antibodies reacted efficiently with WT HK/14 NA ( Fig. 3a) ; however, most of these antibodies exhibited reduced binding to HK-245N and HK-245N/247T. Some antibodies, that is, 229-1D05, 229-1G03, 235-1C02, 235-1E06 and B10, had substantially reduced or no binding. The S245N/S247T/P468H triple mutation, which resulted in significantly reduced inhibition of NA by ferret and human antisera against HK/14, caused further reduced binding of NA by the monoclonal antibodies 228-2D04 and 229-1A02. The reduced or abolished binding was also observed with WT SGP/16 NA; however, these antibodies largely recovered binding with the introduction of a N245S mutation ( Fig. 3b ). Interestingly, the H468P mutation did not enhance the binding of SGP/16 NA by the tested antibodies. These data demonstrate that 2 2 9 -1 G 0 3 2 2 9 -1 F 0 6 2 2 9 -2 C 0 6 2 2 9 -2 E 0 2 2 2 9 -2 G 0 5 2 2 9 -1 A 0 2 2 2 9 -1 B 0 5 2 2 9 -2 B 0 4 2 2 9 -1 D 0 5 2 2 9 -1 G 0 3 2 2 9 -1 F 0 6 2 2 9 -2 C 0 6 2 2 9 -2 E 0 2 2 2 9 -2 G 0 5 NA with H468P mutation. The binding was measured by ELISA using A(H6N2) viruses carrying each of the WT and mutant NAs. The antibodies were applied at 1 µg ml −1 . Mouse antisera against A(H3N2) virus were used as positive controls. Virus in negative control 1 was detected by the N1-specific antibody 3A2 (ref. 21 ) and peroxidase-conjugated goat-anti-mouse IgG; virus in negative control 2 was detected by the antibody 3A2 and peroxidase-conjugated goat-anti-human IgG. The mean OD 490 values from one of two technically independent assays that were run in duplicate and yielded similar results are shown (data from the other assays are shown in Supplementary Fig. 8 ).
the glycosylation at NA245 interfered with the binding of NA by human monoclonal antibodies, which is consistent with the NA antigenic drift observed with human sera.
Structural basis for the NA antigenic drift. We next wanted to explore the structural basis for the observed NA antigenic change; we focused on the NA245 glycosylation site because it has a profound impact on the binding of NA by human and mouse antibodies (Fig. 3) . The crystal structure of the Fab of antibody B10 in complex with MN/10 NA was solved at 2.3 Å (Supplementary Table 6 ). Similar to previously reported NA-Fab complexes 20,23-25 , each B10 Fab binds to one NA monomer (Fig. 4a) , and both the heavy (H) and light (L) chains contribute to the antibody footprint (Fig. 4b) . The areas 26 on the NA surface buried by the B10 H and L chains are 457 Å 2 and 399 Å 2 , respectively. The NA residues contacted by the H chain are H150, D151, R152, D198, N199, R292, N294, H347 and K431, and those contacted by the L chain are S245, S247, R292, N294 and N342 (Fig. 5a ). Fourteen amino acids, eight from the B10 H chain and six from the L chain, are involved in the binding of NA ( Fig. 5b and Supplementary Table 7 ). The complementary determining region 3 (CDR3) of the B10 H chain inserts into the NA active site, with Y102 forming a hydrogen bond with NA residues 292 and 294 ( Fig. 5c and Supplementary Table 7 ). The B10 L-chain residue S92 within CDR3 forms a hydrogen bond with the NA residue S245 and the L-chain residues S32 and Y91-located in CDR1 and CDR3, respectively-form hydrogen bonds with NA residue 247. The NA active site includes eight highly conserved residues (R118, D151, R152, R224, E276, R292, R371 and Y406) that are key for the catalytic function 27 ; furthermore, the active site is structurally stabilized through a network of hydrogen bonds and salt bridges by a constellation of largely conserved framework residues (E119, R156, W178, S179, D198, I222, E227, H274, E277, N294 and E425). Among these residues, D151, R152, D198, R292 and N294 are in the B10 epitope and interact with the B10 H chain ( Supplementary  Table 7 ). Thus, the B10 epitope overlaps the NA active site and involves five residues that are functionally or structurally critical to the enzymatic activity.
NA antigenic drift results in reduced in vivo protection.
Given the NA antigenic drift demonstrated by the in vitro assays, we conducted mouse experiments to assess whether it is associated with reduced protection against virus infection. The first experiment was a passive serum-transfer study. Mice were intraperitoneally injected with ferret antisera against HK/14 diluted to an NI titre of 320 and challenged intranasally with H6N2 HK/14 or H6N2 SGP/16 virus 16 h later. This passive serum-transfer strategy ensured that the difference in protection was probably due to NA-specific antibodies. The HK/14 ferret antisera protected all mice against challenge with H6N2 HK/14 but protected only one of five mice from death caused by H6N2 SGP/16 (Fig. 6a,b ). The mice that received HK/14 ferret antisera had an approximately 100-fold reduction in the virus load of H6N2 HK/14 in the lungs compared with the control mice that received sera from naive ferrets. These data suggest that NA antigenic drift reduced protection against virus infection provided by NA-specific serum antibodies.
In the second mouse experiment, we immunized mice with recombinant MN/10 NA before virus challenge. The MN/10 NA was selected because it shares the B10 epitope with the HK/14 but not the SGP/16 NA ( Supplementary Fig. 5 and Supplementary Tables  4,5 ). The mice were challenged intranasally with either H6N2 HK/14 or H6N2 SGP/16 after being primed and intramuscularly boosted with MN/10 NA, using poly(I:C) as an adjuvant. The animals challenged with H6N2 HK/14 experienced a slight weight loss and four of five mice survived. In contrast, animals challenged with H6N2 SGP/16 experienced significant weight loss and all died (Fig. 6c,d) , similar to the control animals that were primed and boosted only with poly(I:C) before virus challenge. The finding from this second mouse experiment adds evidence that NA antigenic drift of A(H3N2) viruses contributed to the reduced protection against virus infection.
Discussion
Our study demonstrates that the NA of the circulating A(H3N2) viruses during the influenza seasons of 2016-17 and 2017-18 in the Northern Hemisphere and 2016 and 2017 in the Southern Hemisphere was antigenically distinct from the HK/14-like vaccine strains. Based on the findings from our in vitro assays and in vivo experiments, we propose that this NA antigenic drift, which is mainly caused by the acquisition of the NA245 glycosylation site (due to the S245N/S247T substitutions) and the P468H mutation, might have impacted NA-antibody-based protection against A(H3N2) virus infection. The observed NA antigenic drift did not result solely from the NA245 glycosylation site; however, this glycosylation site is now present in nearly all circulating A(H3N2) strains ( Fig. 1b ) and we provide structural evidence that it is within a unique epitope. This epitope, defined by the mouse B10 antibody, overlaps the NA active site (Fig. 5 ). Amino acid mutations introduced in this epitope may directly impact the antibody-antigen interaction and more drastic changes (for example, glycans added to residue 245) sterically hinder antibody binding ( Supplementary Fig. 6 ). The S245N single mutation impacted the binding of the HK/14 NA by antibodies such as 229-1A02 and 235-1C02, and the S245N/ S247T double mutation further reduced binding by some of the tested antibodies (Fig. 3a) . This was probably due to a more complete glycosylation at residue 245 resulting from the double mutation ( Fig. 1c) to facilitate the escape from antibody inhibition, which would explain why the double mutation has become predominant in the NA of the circulating A(H3N2) viruses (Fig. 1b) . The human antibodies 235-1C02 and 235-1E06 reacted with the NAs of contemporary seasonal A(H3N2) viruses (for example, SWZ/13 and HK/14), pandemic A(H3N2) virus A/Hong Kong/1/1968 and A(H2N2) virus A/Singapore/1/1957 (ref. 22 ), and probably also target the B10 epitope ( Supplementary Fig. 7) . Thus, the NA245 glycosylation site disrupted a highly conserved epitope that overlaps the NA active site and contributed to the observed NA antigenic drift. The P468H mutation in NA became prevalent in circulating A(H3N2) viruses in 2016 ( Supplementary  Fig. 4 ) and has also contributed to the NA antigenic change ( Fig. 2 and Supplementary Tables 2,3 ). The H468P back mutation in the SGP/16 NA did not result in enhanced binding, as observed with the N245S mutation; however, in the presence of the S245N/S247T substitutions, P468H further reduced the binding of the HK/14 NA by some antibodies, for example, 229-1A02 and 228-2D04 ( Fig. 3) . Unfortunately, residue 468 is not critical for the binding of NA by any of the antibodies available to us and more efforts are needed to elucidate the role of the mutation at residue 468 in the distinct NA antigenicity.
Although NA content is not standardized in seasonal influenza vaccines and varies with different vaccines, humans do develop NA-specific antibodies, probably due to the NA contained in the vaccines administered [28] [29] [30] [31] or natural virus infection 22 . Antibodies specific to NA have been recognized as a potential independent correlate of protection against influenza virus infection 13, 32 . Most of the human serum samples tested in our assays exhibited high NI antibody titres against HK/14 ( Fig. 2b and Supplementary Table 3 ). However, the NI antibody titres against the tested NAs of circulating viruses (MIE/16, SGP/16 and LA/17) were ≥4-fold lower than those for the HK/14 NA for approximately 50% of the tested human serum samples. The reduced inhibition by NA-specific antibodies might have resulted in a less effective in vivo protection. This is supported by our mouse experiments, which indicated that ferret antisera against HK/14 provided protection against challenge with A(H6N2) virus carrying the HK/14 NA but not the virus possessing the antigenically drifted SGP/16 NA.
A(H3N2) viruses undergo more frequent genetic and antigenic changes than the A(H1N1) and influenza B viruses, necessitating frequent update of the A(H3N2) vaccine strains 33 . The World Health Organization currently selects influenza candidate vaccine viruses based on the HA antigenicity of the circulating viruses; our findings support continued surveillance of the NA of influenza viruses and the inclusion of NA antigenicity for consideration in optimizing influenza vaccines. Northern Hemisphere and 2018 Southern Hemisphere influenza seasons. All of the reassortant A(H6N2) and A(H3N2) viruses bear the internal genes from the A(H1N1) virus A/Puerto Rico/8/1934. These viruses were rescued with reverse genetics 34 and amino acid mutations were introduced into the HK/14 and SGP/16 NAs with a QuikChange multisite-directed mutagenesis kit (Stratagene). Viruses were propagated in 9-to 11-day-old specific-pathogen-free embryonated chicken eggs and titrated in Madin-Darby canine kidney (MDCK) cells, and those used for ELISA were inactivated with β-propiolactone (Sigma-Aldrich) and purified by sucrose gradient centrifugation.
Methods

Viruses. The viruses used in this study include reassortant A(H6N2) viruses that contain the HA gene of A/turkey/Massachusetts
Monoclonal antibodies. Monoclonal mouse antibodies were prepared according to routine hybridoma procedures 21 . Briefly, six-week-old BALB/c mice (The Jackson Laboratory) were intramuscularly immunized with purified MN/10 virus and boosted intravenously on day 3 before the fusion of splenocytes with Sp2/0 cells. Hybridomas secreting N2-specific antibodies were subcloned by limiting dilution. The antibodies were purified using protein G columns (GE Healthcare). The variable regions of the H and L chains of the antibodies were sequenced by ProMab Biotechnologies, Inc. and GenScript Inc. Human antibodies specific to N2 were generated from human peripheral lymph cells as reported 22 . 35 ). The sequence patterns at positions 245, 247 and 468 were analysed using a Perl program and the number of each pattern (245S-247S, 245S-247T, 245N-247S, 245N-247T, 468P, 468H and 468L) was stratified by year.
Western blotting.
Purified virus corresponding to 1 µg of viral protein was denatured, separated by SDS-PAGE in a 10% bis-Tris precast gel with MOPS running buffer in the presence of reducing agent (Invitrogen) and transferred onto a nitrocellulose membrane using an iBlot gel transfer device (Invitrogen). The NA was detected with N2-specific rabbit antiserum (Sino Biological) and Odyssey IRDye 680RD secondary goat-anti-rabbit antibody (LI-COR), and the target bands were visualized using the Odyssey imaging system (LI-COR).
Glycosylation analysis. Proteins were extracted from viruses using 8 M urea in 1 M NH 4 HCO 3 (ref. 36 ), reduced using 12 mM dithiothreitol at 37 °C for 1 h, which was followed by alkylation using 16 mM iodoacetamide at room temperature for 1 h. The samples were diluted with water and trypsin (Promega) was added at a trypsin-to-protein ratio of 1:50 and incubated overnight at 37 °C. The digest was dried in a Speed-Vac vacuum (Thermo Fisher) and resuspended in 80% acetonitrile in the presence of 0.1% trifluoroacetic acid. Glycopeptides were enriched with a hydrophilic interaction liquid chromatography-solid phase extraction column 37 . The eluate was dried in a Speed-Vac vacuum and resuspended in 0.2% formic acid for analysis with liquid chromatography with tandem mass spectrometry. Mass spectrometry was performed using an UltiMate LC and a Fusion Orbitrap mass spectrometer (Thermo Fisher). Glycopeptides (1 µg) were loaded onto a C18 trap cartridge (Waters) and further separated using an Easy-Spray C18 column (Waters). The collision energy was set as 27 and the automatic gain control targets were 1.0 × 10 4 ; the other parameters were the same as described in previous studies 38 . The prediction of N-linked glycosylation for the WT and mutant was performed using NetNGlyc 39 , with scores >0.5 representing a high probability of glycosylation. Glycan structures were inferred based on experimental data, presence in the GlyTouCAn (https://glytoucan.org) and Consortium for Functional Glycomics (www.functionalglycomics.org) glycan databases, and consistency with those structures found in Gallus gallus or their close relatives 40, 41 .
ELISA. The binding of monoclonal antibodies to NA was measured by ELISA. Immulon 2HB flat-bottom microtiter plates (Thermo Scientific) were coated with purified viruses at 10 µg ml −1 (100 µl well −1 ), blocked with 15% fetal bovine serum (Atlanta Biologics) in PBS, and then incubated with antibody (1 µg ml −1 ) and peroxidase-conjugated goat-anti-mouse IgG (Sigma-Aldrich) or goat-antihuman IgG (SouthernBiotech). To examine the competition for binding of the B10 epitope by different antibodies, plates were coated with purified H6N2 HK/14 virus (10 µg ml −1 ; 100 µl well −1 ) and blocked, followed by incubation with a peroxidase-conjugated B10 antibody dilution (prepared in our laboratory using a peroxidase labelling kit (Roche)) supplemented with various concentrations of the tested antibodies. After the signals were developed using o-phenylenediamine dihydrochloride (Sigma-Aldrich) as a substrate, the reaction was stopped with 1 N H 2 SO 4 and the OD 490 values were read.
MU-NANA assay. The NA activity of virus was measured by a MU-NANA assay 18, 19 . Virus was 2-fold serially diluted with PBS (pH 7.4) containing MgCl 2 and CaCl 2 (KD Medical), and mixed with an equal volume (50 µl) of 100 µM MU-NANA (Sigma-Aldrich) in a Microfluor 1 black flat-bottom microtiter plate (Thermo Scientific), followed by incubation at 37 °C for 1 h. The reaction was stopped with 0.1 M glycine in 25% ethanol (pH 10.7) and the signals were read (excitation wavelength, 355 nm; emission wavelength, 460 nm).
NI assay. The inhibition of NA activity was measured with enzyme-linked lectin 17 and MU-NANA 18,19 assays, as described previously. To perform the enzymelinked lectin assays, serial dilutions of antisera or antibodies were mixed with a predetermined amount of virus diluted in MES-buffered saline (pH 6.5; KD Medical) containing 1% bovine serum albumin (Sigma-Aldrich) and 0.5% Tween 20 (Sigma-Aldrich). The mixture was added to 96-well plates (Thermo Scientific) coated with fetuin (Sigma-Aldrich) and incubated overnight at 37 °C. The plates were washed with PBS containing 0.05% Tween 20 (PBST), followed by the addition of peanut agglutinin conjugated to peroxidase (Sigma-Aldrich). The plates were incubated at room temperature for 2 h in the dark and washed with PBST before the addition of the substrate o-phenylenediamine dihydrochloride. The reaction was stopped by adding 1 N H 2 SO 4 and the OD 490 values were read. To measure the inhibition of NA activity with the MU-NANA assay, a predetermined amount of virus was mixed with serial dilutions of antibody and incubated in the Microfluor 1 black flat-bottom microtiter plates (Thermo Scientific) at 37 °C for 1 h, followed by the addition of 100 µM MU-NANA (Sigma-Aldrich) and incubation at 37 °C for 1 h. The reaction was stopped by the addition of 0.1 M glycine in 25% ethanol (pH 10.7) and the signals were read (excitation wavelength, 355 nm; emission wavelength, 460 nm). The NI titre was expressed as the reciprocal of the highest dilution that exhibited ≥50% inhibition of NA activity for both assays.
Construction of the antigenic cartography. Antigenic cartography was constructed on the basis of NI data using AntigenMap (http://sysbio.cvm.msstate. edu/AntigenMap) 42, 43 . Each entry in the NI table was normalized by dividing by the maximum NI value for the reference antiserum. Missing NI titres and those below the cutoff value for low reactors were analysed by low-rank matrix completion. A titre of ten was used as the low-reactor cutoff in the NI assay. The antigenic distance between two viruses was defined as the Euclidean distance between the NI values of the two viruses against all of the antisera. Each unit of the antigenic distance corresponded to a 2-fold change in NI titre. Multi-dimensional scaling was used to project viruses to a two-dimensional map by minimizing the sumsquared error between the map distance and the antigenic distance.
Plaque assay. MDCK cells growing in six-well plates were infected with diluted virus for 1 h at 37 °C. After the virus inoculum was removed and washed with PBS, the cells were overlaid with agar supplemented with 1 µg ml −1 trypsin (Sigma-Aldrich). The agar was supplemented with trypsin (1 µg ml −1 ) and antibody (1-2 µg ml −1 ) to identify the antibody escape mutants. The cells were incubated at 37 °C in 5% CO 2 for 3 d, fixed with methanol and then stained with crystal-violet solution to visualize the plaques.
Selection of antibody escape mutants. Briefly, 0.5 ml ascitic fluid containing monoclonal antibodies or purified monoclonal antibodies (1-2 mg ml −1 ) was incubated with 10 6 plaque-forming units of virus and inoculated into eggs.
The potential escape variants were identified by a haemagglutination assay and further cloned in a plaque assay in the presence of the antibody. Three plaques that were larger than those formed by the parental virus were picked for each variant and propagated in eggs. The allantoic fluid was collected and the NA gene was sequenced. The sequences were analysed using DNASTAR Lasergene software version 14 (DNASTAR) to identify the nucleotide and amino acid changes.
NA expression and purification. The recombinant MN/10 NA-which contains an N-terminal His-tag, tetramerization domain from the human vasodilatorstimulated phosphoprotein and a thrombin cleavage site-was expressed using a baculovirus system. Secreted NA in the culture supernatant was purified by metal affinity chromatography and size-exclusion chromatography. The protein was further subjected to trypsin cleavage and size-exclusion chromatography for the structural analyses.
Formation and purification of the Fab-NA complex. The Fab of the antibody B10 (prepared by SouthernBiotech from purified B10 antibody) was mixed with purified, His-tag-depleted, recombinant MN/10 NA monomer at a 1:1 molar ratio of Fab to NA. The B10 Fab-MN/10 NA complex was purified from unbound substrates by size-exclusion chromatography in a buffer comprising 50 mM Tris-HCl (pH 8.0) and 150 mM NaCl, eluted as a single peak between the 158-and 670-kDa molecular weight markers, and then concentrated to 14 mg ml −1 .
Crystallization and data collection of the Fab-NA complex. Initial sparsematrix crystallization screening was carried out using Formulatrix NT8. Following optimization, diffraction quality crystals were obtained at 23 °C using the sittingdrop vapour-diffusion method against a reservoir containing 0.1 M Tris-HCl (pH 8.5) and 2 M ammonium sulphate (MCSG-1, condition 70; Anatrace). The complex dataset was collected from a single crystal to a resolution of 2.3 Å at the Advanced Photon Source (https://www.aps.anl.gov) SER-CAT 22-ID beamline (1.0 Å wavelength) and data were processed with the DENZO-SCALEPACK suite 44 .
Structure determination and refinement. The structure of the B10 Fab-MN/10 NA complex was determined by the molecular replacement method using the program Phaser 45 Rigid-body and restrained refinement of the molecular replacement solution was carried out using REFMAC5 (ref. 46 ), and model building was performed in Coot 47 . The 2F o -F c electron density was well defined throughout the model. Additional positive electron density was observed in the region of three potential N-linked glycosylation sites. Nine sugar residues were manually fitted into this density at these positions. Restrained refinement of the structure was completed in REFMAC5 using TLS refinement 48 . The final model was assessed using MolProbity 49 . All of the statistics for data processing and refinement are presented in Supplementary Table 6 . In the final model, 95% of the residues were in favoured regions of a Ramachandran plot and the other 5% were in additional allowed regions.
Animal experiments.
Two mouse experiments were conducted to examine the in vivo impact of NA antigenic drift and federal guidelines and protocols approved by the Food and Drug Administration Institutional Animal Care and Use Committee were followed. The first experiment was a passive serumtransfer study, in which groups of 11 DBA/2 mice (twelve-weeks old; The Jackson Laboratory) were intraperitoneally injected with ferret antisera against HK/14 (0.2 ml per animal), which were diluted with PBS to an NI titre of 320, or pooled naive ferret sera (NI titre < 10) diluted to the same fold as for the HK/14 ferret antisera; the mice were intranasally challenged 16 h later with 10 LD 50 of H6N2 HK/14 or H6N2 SGP/16 viruses in 50 µl PBS. In the second experiment, groups of 11 DBA/2 mice (six-weeks old; The Jackson Laboratory) were intramuscularly immunized with recombinant MN/10 NA (5 µg per mouse) administered together with poly(I:C) adjuvant (Sigma-Aldrich) and boosted with the same dose of NA with adjuvant at three weeks after the priming. The animals were intranasally challenged with 10 LD 50 of H6N2 HK/14 or H6N2 SGP/16 in 50 µl PBS three weeks after the boost. In both experiments, six mice from each group were euthanized on days 3 and 6 (three animals each day) after virus challenge and the lungs were sampled for virus titration in MDCK cells; the remaining five mice from each group were monitored for survival and loss in body weight for up to 14 d; the mice that had 25% weight loss were euthanized. Corresponding author(s): Hongquan Wan Last updated by author(s): Jun 12, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code Data collection NA protein sequences were downloaded from public databases including GISAID (the Global Initiative on Sharing All Influenza Data; http://www.gisaid.org), the Influenza Research Database (https://www.fludb.org), and the Influenza Virus Resource (https:// www.ncbi.nlm.nih.gov/genomes/FLU/); the complex dataset was collected at the Advanced Photon Source (https://www.aps.anl.gov/).
Data analysis
NA protein sequences were analyzed with Muscle v3.8.31 and a Perl program, and NA nucleotide sequences were analyzed with DNASTAR Lasergene 14 software; prediction of N-linked glycosylation was performed with NetNGlyc; antigenic cartography was constructed with AntigenMap (http://sysbio.cvm.msstate.edu/AntigenMap); CDR regions of the H and L chains of antibody were defined with IMGT/V-QUEST; rigid-body and restrained refinement of the molecular replacement solution was carried out using REFMAC5, model building was performed in Coot, and the final model was assessed using MolProbity; statistical analyses were performed with GraphPad Prism version 7.0, images in Supplementary Fig.5 were generated using PyMOL software.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Data that support the findings of this study are available from the corresponding author upon request. Atomic coordinates and structure factors for the B10 Fab-MN/10 NA complex have been deposited to the protein Data Bank (www.pdb.org) under the accession code 6N6B.
